These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 19997080)

  • 1. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions.
    Correia CT; Almeida JP; Santos PE; Sequeira AF; Marques CE; Miguel TS; Abreu RL; Oliveira GG; Vicente AM
    Pharmacogenomics J; 2010 Oct; 10(5):418-30. PubMed ID: 19997080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone-related weight gain: genetic and nongenetic predictors.
    Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
    J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of clinical response to risperidone.
    Llerena A; Berecz R; Peñas-Lledó E; Süveges A; Fariñas H
    Pharmacogenomics; 2013 Jan; 14(2):177-94. PubMed ID: 23327578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.
    Anderson GM; Scahill L; McCracken JT; McDougle CJ; Aman MG; Tierney E; Arnold LE; Martin A; Katsovich L; Posey DJ; Shah B; Vitiello B
    Biol Psychiatry; 2007 Feb; 61(4):545-50. PubMed ID: 16730335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting.
    Kim B; Choi EY; Kim CY; Song K; Joo YH
    Hum Psychopharmacol; 2008 Jan; 23(1):61-7. PubMed ID: 17924589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of Risperidone-Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder.
    Sukasem C; Vanwong N; Srisawasdi P; Ngamsamut N; Nuntamool N; Hongkaew Y; Puangpetch A; Chamkrachangpada B; Limsila P
    Basic Clin Pharmacol Toxicol; 2018 Jul; 123(1):42-50. PubMed ID: 29369497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The polymorphisms of candidate pharmacokinetic and pharmacodynamic genes and their pharmacogenetic impacts on the effectiveness of risperidone maintenance therapy among Saudi children with autism.
    Shilbayeh SAR; Adeen IS; Alhazmi AS; Aljurayb H; Altokhais RS; Alhowaish N; Aldilaijan KE; Kamal M; Alnakhli AM
    Eur J Clin Pharmacol; 2024 Jun; 80(6):869-890. PubMed ID: 38421437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone.
    McDougle CJ; Scahill L; McCracken JT; Aman MG; Tierney E; Arnold LE; Freeman BJ; Martin A; McGough JJ; Cronin P; Posey DJ; Riddle MA; Ritz L; Swiezy NB; Vitiello B; Volkmar FR; Votolato NA; Walson P
    Child Adolesc Psychiatr Clin N Am; 2000 Jan; 9(1):201-24. PubMed ID: 10674197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
    Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
    Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone: new indication. Behavioural disorders in children with autism or mental disabilities: no progress.
    Prescrire Int; 2006 Apr; 15(82):43-5. PubMed ID: 16602211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.
    Yamanouchi Y; Iwata N; Suzuki T; Kitajima T; Ikeda M; Ozaki N
    Pharmacogenomics J; 2003; 3(6):356-61. PubMed ID: 14610521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects.
    Choong E; Polari A; Kamdem RH; Gervasoni N; Spisla C; Jaquenoud Sirot E; Bickel GG; Bondolfi G; Conus P; Eap CB
    J Clin Psychopharmacol; 2013 Jun; 33(3):289-98. PubMed ID: 23609392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness.
    Malone RP; Maislin G; Choudhury MS; Gifford C; Delaney MA
    J Am Acad Child Adolesc Psychiatry; 2002 Feb; 41(2):140-7. PubMed ID: 11837403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone use in the treatment of behavioral symptoms in children with autism.
    West L; Waldrop J
    Pediatr Nurs; 2006; 32(6):545-9. PubMed ID: 17256292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism.
    Akhondzadeh S; Fallah J; Mohammadi MR; Imani R; Mohammadi M; Salehi B; Ghanizadeh A; Raznahan M; Mohebbi-Rasa S; Rezazadeh SA; Forghani S
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):32-6. PubMed ID: 19772883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open clinical trial of risperidone monotherapy in young children with autistic disorder.
    Findling RL; Maxwell K; Wiznitzer M
    Psychopharmacol Bull; 1997; 33(1):155-9. PubMed ID: 9133768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study.
    Troost PW; Lahuis BE; Steenhuis MP; Ketelaars CE; Buitelaar JK; van Engeland H; Scahill L; Minderaa RB; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2005 Nov; 44(11):1137-44. PubMed ID: 16239862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.
    Roke Y; van Harten PN; Franke B; Galesloot TE; Boot AM; Buitelaar JK
    Pharmacogenet Genomics; 2013 Sep; 23(9):487-93. PubMed ID: 23851570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.
    Yasui-Furukori N; Saito M; Tsuchimine S; Nakagami T; Sato Y; Sugawara N; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1491-5. PubMed ID: 18579277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open trial of risperidone in 24 young children with pervasive developmental disorders.
    Masi G; Cosenza A; Mucci M; Brovedani P
    J Am Acad Child Adolesc Psychiatry; 2001 Oct; 40(10):1206-14. PubMed ID: 11589534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.